Journals / Osteoporoz Dünyasından / 2006 / Cilt: 12 - Sayı: 3

Changes in serum and urine N-Telopeptide levels of postmenopausal osteoporotic patients within 6-months of risedronate treatment

Postmenopozal osteoporozlu hastalarda 6 aylık risedronat tedavisi ile serum ve ıdrar N-Telopeptid düzeylerinin değişimi

Pages
55–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore they can be used as an alternative and adjunct method to bone densitometry to assess the response to treatment, especially to demonstrate the early changes. (Osteoporoz Dünyasından 2006;12:55-9)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: N-Telopeptides (NTX), which are known as bone turnover markers are being increasingly used in early diagnosis of osteoporosis, determining the fracture risk and following up of the treatment outcome.
📊
Key Findings & Data:Material and Method: In this study serum and urine NTX levels of postmenapousal patients [ages 60-83 (mean 69.45), n: 11] with no previous treatment of osteoporosis are compared with the levels after 6-months of risedronate treatment and serum and urine NTX levels of the control group [ages 57-73 (mean 64.64), n: 11].
💡
Conclusion & Impact:Therefore they can be used as an alternative and adjunct method to bone densitometry to assess the response to treatment, especially to demonstrate the early changes. (Osteoporoz Dünyasından 2006;12:55-9)
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: N-Telopeptides (NTX), which are known as bone turnover markers are being increasingly used in early diagnosis of osteoporosis, determining the fracture risk and following up of the treatment outcome. Material and Method: In this study serum and urine NTX levels of postmenapousal patients [ages 60-83 (mean 69.45), n: 11] with no previous treatment of osteoporosis are compared with the levels after 6-months of risedronate treatment and serum and urine NTX levels of the control group [ages 57-73 (mean 64.64), n: 11]. Results: Consequently serum NTX (sNTX) levels of postmenapousal patients before risedronate therapy were significantly higher then the sNTX levels of the control group. After risedronate therapy sNTX levels were significantly higher and urine (uNTX) levels were lower when compared with the NTX levels before treatment. Also either sNTX or uNTX levels before and after the treatment were positively and strongly correlated. Discussion and Conclusion: Eventually bone turnover markers carry much importance in diagnosis and follow-up the treatment. Also the strong correlation between levels of NTX before and after the treatment shows that the sensitivity and specifity of these methods are high. Therefore they can be used as an alternative and adjunct method to bone densitometry to assess the response to treatment, especially to demonstrate the early changes. (Osteoporoz Dünyasından 2006;12:55-9)

Özet

Amaç: Kemik döngü belirteçleri olan N-telopeptidlerin (NTX) osteoporozun erken tanısında, kemik kırık riskini belirlemede ve tedaviyi takipte kullanımı giderek yaygınlaşmaktadır. Gereç ve Yöntem: Bu çalışmada tedavi edilmemiş postmenopozal osteoporozu olan 11 hastanın (60-83 yaş arası, ortalama yaş 69,45) 6 aylık risedronat tedavisi öncesi ve sonrası serum ve idrar N-telopeptid düzeyleri ve yaş uyumlu 11 gönüllüde oluşan kontrol grubunun (57-73 yaş arası, ortalama yaş 64,64) serum ve idrar NTX değerleri karşılaştırılmıştır. Bulgular: Yapılan incelemelerde postmenopozal hasta grubunun tedavi öncesi serum NTX (sNTX) düzeyleri kontrol grubuna göre anlamlı düzeyde düşük bulundu. Tedavi sonrası sonuçlar karşılaştırıldığında ise sNTX düzeyleri tedavi öncesine göre anlamlı derecede yüksekken tersine idrar NTX (iNTX) düzeyleri anlamlı derecede düşüktü. Ayrıca tedavi öncesi ve sonrası hem idrar (r: 0,909) hem de serum NTX (r: 0,700) düzeyleri arasında kuvvetli pozitif bir ilişki olduğu gözlendi. Sonuç: Sonuç olarak kemik döngü belirteçleri osteoporozun tanısında ve tedavinin takibinde önemli yer tutmaktadır. Ayrıca tedavi sonrası ve öncesi idrar ve serum NTX düzeyleri arasındaki negatif ancak kuvvetli ilişki bu yöntemlerin duyarlılık ve özgüllüğünün yüksek olabileceğini düşündürmüştür. Bu nedenle tedaviye yanıtın değerlendirilmesinde, özellikle erken değişiklilerin ortaya konulmasında kemik dansitometrisine bir alternatif ya da yardımcı olarak kullanılabileceği sonucuna varılabilir. (Osteoporoz Dünyasından 2006;12:55-9)

🔖

Cite This Article

ZİNNUROĞLU, M., SEPİCİ, V., KARATAŞ, K. G., DİNÇEL, A. S. (2006). Changes in serum and urine N-Telopeptide levels of postmenopausal osteoporotic patients within 6-months of risedronate treatment. Osteoporoz Dünyasından, Cilt: 12 - Sayı: 3, 55–59. https://ajindex.com/articles/286818

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kim SW, Park do Jve ark. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2005;52:667-74
  2. Iwamoto J, Takeda T ve ark Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J. 2005;46:750-8
  3. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79:1693-700
  4. Takahashi M, Kawana K ve ark. Biological variability of biochemical markers of bone turnover in healthy women. Endocr Res. 2002;28:257-64
  5. Seibel MJ, Lang M ve ark. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem. 2001;47:1443-50
  6. Seibel MJ, Meier C ve ark. Seasonal variation of bone turnover? J Bone Miner Res. 2004;19:168-9
  7. Heshmati HM, Riggs BL ve ark. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab. 1998;83:751-6
  8. Gertz BJ, Clemens JD ve ark. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998;63:102-6
  9. Greenspan SL, Rosen HN ve ark. Early changes in serum Ntelopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537-40
  10. Eastell R, Mallinak N ve ark. Chesnut C 3rd. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res. 2000;15:594-8
  11. Ledger GA, Burritt MF ve ark. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab. 1995;80:3304-10
  12. Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta. 2001;313:95-105
  13. Leung JY, Ho AY, Ip TP ve ark. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo- controlled study. Bone. 2005;36:358-64
  14. Iwamoto J, Takeda T ve ark. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopau